- Home
- STRO vs AVIR Comparison
STRO vs AVIR Comparison
Compare STRO & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- AVIR
- Stock Information
- Founded
- STRO 2003
- AVIR 2012
- Country
- STRO United States
- AVIR United States
- Employees
- STRO N/A
- AVIR N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- STRO Health Care
- AVIR Health Care
- Exchange
- STRO Nasdaq
- AVIR Nasdaq
- Market Cap
- STRO 77.7M
- AVIR 273.0M
- IPO Year
- STRO 2018
- AVIR 2020
- Fundamental
- Price
- STRO $0.81
- AVIR $3.72
- Analyst Decision
- STRO Hold
- AVIR Hold
- Analyst Count
- STRO 7
- AVIR 1
- Target Price
- STRO $3.97
- AVIR $6.00
- AVG Volume (30 Days)
- STRO 1.4M
- AVIR 403.3K
- Earning Date
- STRO 08-12-2025
- AVIR 08-06-2025
- Dividend Yield
- STRO N/A
- AVIR N/A
- EPS Growth
- STRO N/A
- AVIR N/A
- EPS
- STRO N/A
- AVIR N/A
- Revenue
- STRO $66,434,000.00
- AVIR N/A
- Revenue This Year
- STRO N/A
- AVIR N/A
- Revenue Next Year
- STRO N/A
- AVIR N/A
- P/E Ratio
- STRO N/A
- AVIR N/A
- Revenue Growth
- STRO N/A
- AVIR N/A
- 52 Week Low
- STRO $0.52
- AVIR $2.46
- 52 Week High
- STRO $5.17
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- STRO 51.04
- AVIR 70.64
- Support Level
- STRO $0.73
- AVIR $3.63
- Resistance Level
- STRO $0.79
- AVIR $3.78
- Average True Range (ATR)
- STRO 0.06
- AVIR 0.14
- MACD
- STRO 0.00
- AVIR 0.02
- Stochastic Oscillator
- STRO 69.90
- AVIR 80.65
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).